Japan Kyowa Industrial

Kyowa Pharmaceutical Industry is a prominent Japanese pharmaceutical company specializing in the development, manufacturing, and distribution of generic medicines, with a strategic focus on the Central Nervous System (CNS) therapeutic area. The company provides a broad portfolio of high-quality generic drugs covering psychiatry, neurology, and internal medicine, including treatments for schizophrenia, depression, and epilepsy. Formerly a subsidiary of the Indian multinational Lupin Limited, the company was acquired by the private equity firm Unison Capital in 2019 to strengthen its position in the Japanese domestic market. Kyowa Pharmaceutical Industry operates multiple manufacturing facilities in Japan, ensuring a stable supply of essential medicines to hospitals and pharmacies nationwide. The company is recognized for its value-added generics, which often feature improved formulations or packaging designed to enhance patient adherence and safety.